))
10: Growing a Multi-National Life Sciences Company
Manage episode 323997247 series 3305030
Conteúdo fornecido por Deepbridge Capital Discovery Podcast and Deepbridge Capital. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Deepbridge Capital Discovery Podcast and Deepbridge Capital ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Paul Colbon (CEO & Co-Founder of Liverpool ChiroChem) joins the Deepbridge Discovery Podcast to discuss the challenges he faced as a co-founder of a university start-up, what the highlights are of being in control of a multi-national company and how Covid-19 has affected Liverpool ChiroChem.
About Liverpool ChiroChem:
Liverpool ChiroChem Ltd operates in the supply chain of pharmaceutical research and development, supplying specialist chemical building blocks that enable laboratory-based researchers to discover and build new drug molecules.
The Company has developed an innovative production process to manufacture its own proprietary chemical compounds for sale, and therefore is able to provide researchers with small volumes of high value chemicals that are currently of high interest but frequently beyond financial reach of resource-constrained research programmes.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
About Liverpool ChiroChem:
Liverpool ChiroChem Ltd operates in the supply chain of pharmaceutical research and development, supplying specialist chemical building blocks that enable laboratory-based researchers to discover and build new drug molecules.
The Company has developed an innovative production process to manufacture its own proprietary chemical compounds for sale, and therefore is able to provide researchers with small volumes of high value chemicals that are currently of high interest but frequently beyond financial reach of resource-constrained research programmes.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
48 episódios
Compartilhar
